We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to…
MMED.E
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release. If you’re not entirely sure what an ETF…
Mind Medicine (MMED.E) announced today their intended acquisition of digital medicine and therapeutics start-up, Healthmode, according to a press release. The acquisition brings access to HealthMode’s intellectual property, as…
Mind Medicine (MMED.E) announced earlier this week their intention to conduct a randomized placebo-controlled study using LSD to evaluate certain health and cognitive effects according to a press release….
The notion of magic mushroom market offering after the legalization of cannabis has been floated time and again since long before cannabis legalization was even on the table. It…
A few states in our neighbour to the south decided to offer psilocybin based therapies during the most recent spate of elections, prompting more potential for companies like Xphyto…
Mind Medicine (MMED.E) closed a bought deal short-form prospectus offering, issuing 27,381,500 units for $1.05 and brought in $28,750,575 today, according to a press release. After the financing, the…
Mind Medicine (MMED.E) is raising money to found and launch a clinical training program focused on developing psychedelic-assisted therapies and medicines at New York University’s (NYU) Langone Health. The…
Scientists don’t have all the answers—if they did they would be out of a job—and sometimes that answer isn’t good enough. Especially for people who are suffering. They want…
Mind Medicine (MMED.E) has worked together with University Hospital Basel’s Liechti Laboratory to discover and file and patent application in the United States for a neutralizer technology that will…